Gensight biologics announces its 2024 financial calendar

Paris--(business wire)--regulatory news: gensight biologics (euronext: sight, isin: fr0013183985, pea-pme eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced its financial calendar for 2024. information date* 2024 1q cash position april 4, 2024 annual general meeting may 29, 2024 2024 2q cash position july 23, 2024 2024 first-half financial update and state.
H Ratings Summary
H Quant Ranking